EA
PGNX

Emerald Acquisition’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Emerald Acquisition’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$778K Buy
122,862
+56,934
+86% +$344K ﹤0.01% 2253
2016
Q2 		$278K Buy
+65,928
New +$318K ﹤0.01% 2652

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's PGNX Position: Q3 2016 in Review

Emerald Acquisition increased its Progenics Pharmaceuticals Inc (PGNX) stake by 86% in Q3 2016, buying an estimated $344K and bringing the position to 122,862 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

Emerald Acquisition first reported a position in PGNX in Q2 2016 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

  • Emerald Acquisition held 122,862 shares of Progenics Pharmaceuticals Inc worth $778K as of Q3 2016.
  • Emerald Acquisition bought 56,934 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $344K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2253 holding.
  • Emerald Acquisition first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.